EPHA2 and melanoma: wtEphB6 restrained the oncogenic signaling of EphA2 and induced anoikis [136], while mutEphB6 (a missense Q926R mutation, found in lung cancers and melanomas) [137,138], promoted cell adhesion-mediated drug resistance (CM-DR) to paclitaxel.